VerImmune’s Post

InduPro, a startup founded by former Merck scientists Scott Lesley, Niyi Fadeyi, and Rob Oslund, has raised $85 million to map and drug protein interactions in cancer and autoimmune disease. One goal is to find new pairs of proteins that can be hit simultaneously for more targeted drugs. Another is to latch onto proteins on different cell surfaces to bring the two cells together. Former Ribon CEO and Flagship and Novartis exec Prakash Raman will lead the startup. Read more in my exclusive story for Endpoints News https://lnkd.in/dm4kV79Y #biotech #startup #seriesA #funding #cancer #cancerdrug #cancertherapy #precisiononcology #immunotherapy #autoimmune #protein #proteinscience

SFBN Feed: Personalis CEO Chris Hall leads a cancer detecting trailblazer https://lnkd.in/gU2r_N8T Finding cancer earlier, and detecting it after treatment, is just part of what sets Personalis apart. Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks #BayArea #SanFrancisco #Biotech #Lifescience #News

I’m happy to share that I’ve obtained a new certification: Maximize Your Cell Health Assays Data Acquisition with Latest Tools in Cancer Research from Thermo Fisher Scientific! Key takeaway: - Overview of various cell health assays in cancer drug discovery #CancerResearch #DrugDiscovery #CellHealth #ProfessionalDevelopment #Webinar #ThermoFisher #Labroots

🌟 Learn. Innovate. Push the boundaries of what's possible. 🌟 In our ever-evolving world, I’m constantly reminded of the importance of staying curious and adaptable. Whether it’s exploring new technologies, diving into recent research, or simply asking, “What if?”, these daily challenges drive us to find creative solutions to complex problems. Did you know there are now more than 300 oncology drugs in development, each with the potential to significantly change how we treat cancer? And that sometimes the most profound solutions come from the most unexpected places—like a sea squirt (also known as ascidian)! Ascidian Therapeutics is leveraging this tiny creature’s unique RNA splicing abilities to develop new treatments for retinal and neurological diseases. Embrace the unknown. Turn challenges into opportunities. #biotech #curiosity

Having a sweet craving? 🍫 Cancer cells are also sweet-tooths who thrive on glucose, the simplest form of sugar. Heightened glucose consumption fuels these cells’ energetic demands, and supports the biosynthesis of essential macromolecules required for cell division and proliferation. However, we have gathered proof that by depriving cancer cells of glucose, we can efficiently target this metabolic weakness by blocking the GLUT1 transporter. Want to know how we do it? Luckily for you, our CSO Mart Ustav Jr. , Medical Director Anu Ustav, and Principal Scientist and lead researcher for the GLUT1 project Siret Tahk will be in #AACR, in San Diego, USA from April 5th - 10th. Presenting this same exact topic in more detail and are open to discussions. Catch them on Monday, April 8th from 9:00 AM - 12:30 PM (poster 1876) or connect via LinkedIn to set up a meeting during the entire conference. #biotechnology #oncology #biomarker

Exciting news! The University of South Australia team, led by Souha H Youssef, has successfully developed biodegradable 3DP bilayer films loaded with 5FU and Cis for the first time. Rigorous characterization and stability testing were conducted to ensure the integrity of the formulation. They also explored the impact of different infill percentages on drug release trends, aiming to modulate drug release. Additionally, MTS assays on HepG2 cells were performed to demonstrate the potential of these films in treating liver cancer. Results were further validated through Western Blotting and other imaging techniques. Special thanks to Souha H Youssef and our entire team for utilizing Nomisma's PLGA 50:50, contributing significantly to advancing research activities. #BiodegradableFilms #DrugDelivery #CancerResearch #Innovation #UniversityofSouthAustralia #Nomisma #PLGA https://lnkd.in/dArxVHkY https://lnkd.in/dP_6mqHN

𝐓𝐡𝐞 𝐠𝐥𝐨𝐛𝐚𝐥 𝐦𝐮𝐥𝐭𝐢 𝐜𝐚𝐧𝐜𝐞𝐫 𝐞𝐚𝐫𝐥𝐲 𝐝𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 𝐦𝐚𝐫𝐤𝐞𝐭 𝐬𝐢𝐳𝐞 𝐢𝐬 𝐞𝐱𝐩𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 𝐔𝐒𝐃 𝟑,𝟗𝟑𝟒.𝟕𝟗 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟐, 𝐞𝐱𝐡𝐢𝐛𝐢𝐭𝐢𝐧𝐠 𝐭𝐡𝐞 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟏𝟔.𝟕% 𝐝𝐮𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐩𝐞𝐫𝐢𝐨𝐝. 𝙁𝙤𝙧 𝙈𝙤𝙧𝙚 𝙍𝙚𝙥𝙤𝙧𝙩 𝘿𝙚𝙩𝙖𝙞𝙡𝙨, 𝙑𝙞𝙨𝙞𝙩: https://lnkd.in/dKP5FxSK   The multi-cancer early detection market is rapidly evolving, driven by advances in genomics, biotechnology, and artificial intelligence. This market focuses on the development and commercialization of diagnostic tests capable of detecting multiple cancer types from a single sample, often using non-invasive methods such as blood tests. The aim is to identify cancer at an early, more treatable stage, improving patient outcomes and reducing healthcare costs. #multicancerearlydetection #cancerdiagnosis #earlydetection #oncology #healthcareinnovation #medicaltechnology #cancerscreening #biotechnology #precisionmedicine #healthcaremarket

AI #Speeds Up Drug #RnD Get ready for a game-changing leap in drug discovery 💡 #Google DeepMind's AlphaProteo #AI designs custom proteins, revolutionizing drug discovery and #cancerResearch. #AlphaProteo creates strong-binding proteins 3 to 300 times more effectively than current methods. Successfully designed binders for 7 out of 8 targets, including cancer-related proteins. Some designs may prevent SARS-CoV-2 from infecting cells, reducing lab work time from years to days. AlphaProteo could lead to faster, more targeted treatments for diseases like cancer and viruses, potentially saving billions in R&D and speeding up life-saving drug discovery. #cancer #AI4cancer #ΑΙsurvivors

The RAS-RAF-MEK-ERK signalling pathway is crucial yet challenging in drug discovery. Advanced assay technologies like live-cell NanoBRET® TE Intracellular Assays for RAS and RAF represent a significant advancement, enabling the creation of biologically relevant models. These tools are vital for understanding the complex biology of cancer progression and therapeutic resistance, paving the way for novel drugs targeting previously undruggable targets. Discover more at https://lnkd.in/eJzZK3Ve #RAS #assays #NanoBRET

In the coming weeks and months, we hope to release a variety of videos that will hopefully help people better understand our business, and the progress we’re making on developing a new effective treatment for cancer. In this video, our CEO, Jeffrey Meckler, shares with you who we are and what we’re working on at #IndaptusTherapeutics.  $INDP #Biotech #CancerResearch #Decoy20